Jubilant Pharmova's consolidated profit declines 36.2%
Drug firm Jubilant Pharmova on Friday reported that its net profit declined 36.24% to Rs 142.84 crore in the quarter ended September 2021 as against Rs 224.03 crore during the previous quarter ended September 2020.
Earnings Call for Q2FY22 of Jubilant Pharmova
Conference Call with Jubilant Pharmova Management and Analysts on Q2FY22 Performance and Outlook. Listen to the full earnings transcript.
Q2FY22 Quarterly Result Announced for Jubilant Pharmova Ltd.
Highlights Revenue was at Rs 1,657 Crore versus Rs 1,591 Crore in Q2'FY21 Reported EBITDA at Rs 344 Crore versus Rs 353 Crore in Q2'FY21 Finance costs at Rs 35 Crore vs. Rs 46 Crore in Q2'FY21 PAT was at Rs 143 Crore as compared with Rs 147 Crore in Q2'FY21 EPS is Rs 8.97 versus Rs 9.21 in Q2'FY21 Capital expenditure for the quarter was Rs 131 Crore Commenting on Company’s performance, Mr. Shyam S Bhartia, Chairman and Mr. Hari S Bhartia, Co-Chairman & Managing Director, Jubilant Pharmova said: “The Company reported 4% topline growth during the quarter driven by steady revenues in the Pharmaceuticals segment and robust growth in the Contract Research and Development Services (CRDS) segment. In the Pharmaceuticals segment, while Radiopharma, Allergy and CMO businesses reported growth on a YoY basis, the API business’ performance was lower on a higher base last year and Generics business witnessed headwinds due to temporary pricing pressure in the US market. The Generics business was also affected during the quarter by the Import Alert at the Roorkee plant and by impact of the Industry wide impurity issue in certain sartan products that led to lower sales and some product withdrawal. In our Contract Research and Development Services business, we witnessed strong growth both YoY and sequentially driven by continued strong demand from our customers for our Drug Discovery Services. In the Proprietary Novel Drugs business, our plans are on track to take one program to the clinical stage by end of this financial year. During H1’FY22, we grew our revenues by 20% YoY and improved our EBITDA margins by 2.44% vs. H1’FY21 due to recovery in Radiopharma business and strong performance in Allergy Immunotherapy, CMO, API and Contract Research businesses. I would like to mention that over the medium term, we have very strong growth levers in all our businesses. To drive growth in these businesses, Company will continue to invest accordingly.” Result PDF Jubilant Pharmova Ltd - 530019 - Jubilant Pharmova Q2 FY 2022
Dear Sirs, In terms of Regulation 33 read with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), we wish to inform you that the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2021 have been approved by the Board of Directors of the Company at its meeting held today at 1:15 p.m. and concluded at 2.45 p.m. Pursuant to the applicable provisions of the Listing Regulations, we enclose the following: 1. The Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2021; 2. Limited Review Reports on the Unaudited Financial Results (Standalone and Consolidated) for the said period; and 3. Copies of the Press Release and Presentation. Jubilant Pharmova Ltd - 530019 - Shareholding for the Period Ended September 30, 2021
Jubilant Pharmova Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2021. For more details, kindly Click here Jubilant Pharmova Ltd - 530019 - Schedule Of Investor Conference Call For Jubilant Pharmova Limited - Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2021
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Company is organising a Conference Call on October 22, 2021 after submission of the financial results for the quarter and half year ended September 30, 2021 to the Stock Exchanges. Details of the Conference Call are attached. Jubilant Pharmova Ltd - 530019 - Board Meeting Intimation for Intimation Of Board Meeting - October 22, 2021
Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/10/2021 ,inter alia, to consider and approve In terms of Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), we wish to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Friday, October 22, 2021, to inter-alia consider Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half-year ended September 30, 2021. Jubilant Pharmova Ltd - 530019 - Statement Of Investor Complaints For The Quarter Ended September 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0110 Name of the Signatory :- Rajiv ShahDesignation :- Company Secretary and Compliance Officer Jubilant Pharmova Ltd - 530019 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 Jubilant Pharmova Ltd - 530019 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to the provisions of Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company has issued duplicate share certificate to the member as per the attachment. This is for your information and record.